---
document_datetime: 2023-09-21 17:20:13
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/hexavac-epar-procedural-steps-taken-authorisation_en.pdf
document_name: hexavac-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5179065
conversion_datetime: 2025-12-31 01:32:02.688532
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Aventis  Pasteur  MSD  S.N.C.,  France  submitted  on  8  July  1999  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for  Hexavac, in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Dr. M. Haase Co-Rapporteur: Dr Pasqualino Rossi Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 30 July 1999. · The Rapporteur's first Assessment Report was circulated to all CPMP  members  on 6 October 1999.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 8 October 1999. · The BWP during its meeting of 9-10 November 1999, adopted the BWP recommendation to be transmitted to the CPMP for endorsement. · During  the  meeting  on  16-18  November  1999  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the company on 18 November 1999. · The applicant submitted the responses to the CPMP consolidated List of Questions on 2 March 2000. · The  Rapporteur's/Co-Rapporteur's  Joint  Assessment  Report  on  the  Applicant's  Response  to CPMP's consolidated List of Questions was circulated to all CPMP members on 20 April 2000. · The  BWP  during  its  meeting  of  16-17  May  2000,  adopted  the  BWP  recommendation  to  be transmitted to the CPMP for endorsement. · An ad hoc expert group meeting on clinical issues was held on 22 May 2000 and a report from this meeting was circulated to all CPMP members on 23 May 2000. · A list of outstanding issues was identified by the CPMP at its meeting on 23-25 May 2000. · The Rapporteur´s/Co-Rapporteur´s pharmaceutical Joint Assessment Report on CPMP´s List of Outstanding Issues was circulated to the CPMP and all BWP members on 14 June 2000. Medicinal product no longer authorised

- The  BWP  during  its  meeting  of  20-21  June  2000,  adopted  the  BWP  recommendation  to  be transmitted to the CPMP for endorsement.
- The company, Aventis Pasteur MSD S.N.C. provided on 29 June 2000, a letter of undertaking on the follow-up measures (pharmaceutical and clinical issues), to be fulfilled as requested by the CPMP.

<div style=\"page-break-after: always\"></div>

- During the meeting on 27-29 June 2000 the CPMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation for Hexavac on 29 June 2000.

<!-- image -->